SG11201501867UA - Novel uses - Google Patents

Novel uses

Info

Publication number
SG11201501867UA
SG11201501867UA SG11201501867UA SG11201501867UA SG11201501867UA SG 11201501867U A SG11201501867U A SG 11201501867UA SG 11201501867U A SG11201501867U A SG 11201501867UA SG 11201501867U A SG11201501867U A SG 11201501867UA SG 11201501867U A SG11201501867U A SG 11201501867UA
Authority
SG
Singapore
Prior art keywords
novel uses
novel
Prior art date
Application number
SG11201501867UA
Other languages
English (en)
Inventor
Ratti Emiliangelo
Trower Michael
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of SG11201501867UA publication Critical patent/SG11201501867UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201501867UA 2012-10-11 2013-10-09 Novel uses SG11201501867UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712499P 2012-10-11 2012-10-11
PCT/EP2013/071093 WO2014057003A1 (en) 2012-10-11 2013-10-09 Novel uses

Publications (1)

Publication Number Publication Date
SG11201501867UA true SG11201501867UA (en) 2015-04-29

Family

ID=49322388

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501867UA SG11201501867UA (en) 2012-10-11 2013-10-09 Novel uses

Country Status (24)

Country Link
US (3) US9603849B2 (de)
EP (2) EP3597192A1 (de)
JP (2) JP6815728B2 (de)
KR (1) KR102202481B1 (de)
CN (1) CN104703603A (de)
AU (1) AU2013328695B9 (de)
BR (1) BR112015006051A2 (de)
CA (1) CA2884454C (de)
CY (1) CY1122313T1 (de)
DK (1) DK2906219T3 (de)
EA (1) EA201590364A1 (de)
ES (1) ES2750662T3 (de)
HK (1) HK1211486A1 (de)
HR (1) HRP20191955T1 (de)
HU (1) HUE046508T2 (de)
IL (1) IL237636B (de)
LT (1) LT2906219T (de)
MX (1) MX362879B (de)
PL (1) PL2906219T3 (de)
PT (1) PT2906219T (de)
RS (1) RS59470B1 (de)
SG (1) SG11201501867UA (de)
SI (1) SI2906219T1 (de)
WO (1) WO2014057003A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2906219T1 (sl) * 2012-10-11 2019-12-31 Nerre Therapeutics Limited Orvepitant za zdravljenje kroničnega pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2017118584A1 (en) * 2016-01-08 2017-07-13 Nerre Therapeutics Limited Orvepitant for the treatment of chronic cough
EP3478283A4 (de) * 2016-06-29 2020-07-22 Menlo Therapeutics Inc. Verwendung von neurokinin-1-antagonisten zur behandlung verschiedener pruriginöser störungen
CN110996908A (zh) 2017-08-11 2020-04-10 株式会社爱茉莉太平洋 包含(r)-n-[1-(3,5-二氟-4-甲磺酰氨基-苯基)-乙基]-3-(2-丙基-6-三氟甲基-吡啶-3-基)-丙烯酰胺的药物组合物
MX2022002646A (es) 2019-09-05 2022-04-26 Incyte Corp Formulacion de ruxolitinib para la reduccion de comezon en dermatitis atopica.
JP7478894B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤
JP7478895B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2728265A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
EP1295599A1 (de) 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Verfahren zur Behandlung oder Verhütung von atopischer Dermatitis
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2006516581A (ja) * 2003-01-27 2006-07-06 グラクソ グループ リミテッド 機能性消化不良を治療するための化学化合物の使用
GB0522061D0 (en) 2005-10-28 2005-12-07 Glaxo Group Ltd Chemical process
AU2008333131B2 (en) * 2007-12-07 2013-10-24 Merck Serono S/A Humanized antibody molecules specific for IL-31
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
US20120077803A1 (en) * 2009-02-24 2012-03-29 Novartis Ag Uses Of NK Receptor Antagonists
EP2683376B1 (de) * 2011-03-07 2018-11-28 Celgene Corporation Verfahren zur behandlung von erkrankungen mit isoindolinverbindungen
CN104245702B (zh) 2012-02-22 2016-09-14 利奥制药有限公司 新型神经激肽1受体拮抗剂化合物
SI2906219T1 (sl) * 2012-10-11 2019-12-31 Nerre Therapeutics Limited Orvepitant za zdravljenje kroničnega pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus

Also Published As

Publication number Publication date
BR112015006051A2 (pt) 2017-07-04
KR20150064732A (ko) 2015-06-11
US20170143711A1 (en) 2017-05-25
EP3597192A1 (de) 2020-01-22
KR102202481B1 (ko) 2021-01-12
SI2906219T1 (sl) 2019-12-31
PL2906219T3 (pl) 2020-02-28
AU2013328695A9 (en) 2018-04-26
RS59470B1 (sr) 2019-11-29
US20150238486A1 (en) 2015-08-27
JP6815728B2 (ja) 2021-01-20
EP2906219A1 (de) 2015-08-19
MX2015004162A (es) 2015-07-06
CA2884454A1 (en) 2014-04-17
AU2013328695B9 (en) 2018-05-17
AU2013328695A1 (en) 2015-04-02
EA201590364A1 (ru) 2015-11-30
EP2906219B1 (de) 2019-08-07
MX362879B (es) 2019-02-21
HRP20191955T1 (hr) 2020-01-24
CA2884454C (en) 2021-07-27
US9603849B2 (en) 2017-03-28
HK1211486A1 (en) 2016-05-27
WO2014057003A1 (en) 2014-04-17
US20190216806A1 (en) 2019-07-18
PT2906219T (pt) 2019-11-04
AU2013328695B2 (en) 2018-04-05
DK2906219T3 (da) 2019-10-28
CN104703603A (zh) 2015-06-10
JP2019131594A (ja) 2019-08-08
CY1122313T1 (el) 2021-01-27
JP6953468B2 (ja) 2021-10-27
IL237636B (en) 2019-01-31
LT2906219T (lt) 2019-10-25
JP2015533136A (ja) 2015-11-19
ES2750662T3 (es) 2020-03-26
IL237636A0 (en) 2015-04-30
HUE046508T2 (hu) 2020-03-30

Similar Documents

Publication Publication Date Title
DK3327112T3 (en) Agse-deficient stamme
EP2754580A4 (de) Kipplader
DK2830816T3 (en) Hidtil ukendt coatingkoncept
HK1204797A1 (en) Novel anti-siglec15 antibody -siglec-15
EP2935220A4 (de) Peri-carbinole
GB201216800D0 (en) Novel use
HK1211486A1 (en) Novel uses
EP2920142A4 (de) Methanfullerene
EP2812698A4 (de) Durch doppelte akzeptorzeit aufgelöster fret
EP2920157A4 (de) Di-macrocyclen
EP2873363A4 (de) Diopsimeter
EP2834250A4 (de) Lithiumsilikate
GB201201720D0 (en) Novel combinations
GB201203307D0 (en) Remvox
GB201222528D0 (en) Novel uses
GB201222391D0 (en) Novel Uses
GB201212393D0 (en) Novel combination
GB201207154D0 (en) Novel form
AU345893S (en) Treehouse
GB201212463D0 (en) Novel use
GB201202256D0 (en) Novel use
GB201203507D0 (en) Keynut
GB201203453D0 (en) TVtidy
GB201203440D0 (en) Blu-seals
GB201203045D0 (en) Chrismar